Protara Therapeutics (TARA) Competitors $3.12 -0.02 (-0.64%) Closing price 04:00 PM EasternExtended Trading$3.12 0.00 (0.00%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. ERAS, ETON, CGEM, TNXP, ITOS, GOSS, RGNX, PRTA, TECX, and EOLSShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Erasca (ERAS), Eton Pharmaceuticals (ETON), Cullinan Therapeutics (CGEM), Tonix Pharmaceuticals (TNXP), iTeos Therapeutics (ITOS), Gossamer Bio (GOSS), REGENXBIO (RGNX), Prothena (PRTA), Tectonic Therapeutic (TECX), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Erasca Eton Pharmaceuticals Cullinan Therapeutics Tonix Pharmaceuticals iTeos Therapeutics Gossamer Bio REGENXBIO Prothena Tectonic Therapeutic Evolus Protara Therapeutics (NASDAQ:TARA) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations. Which has more risk & volatility, TARA or ERAS? Protara Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Is TARA or ERAS more profitable? Erasca's return on equity of -31.19% beat Protara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -36.87% -33.85% Erasca N/A -31.19%-26.34% Which has stronger valuation & earnings, TARA or ERAS? Erasca is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$44.60M-$1.62-1.93ErascaN/AN/A-$161.65M-$0.45-3.49 Does the media favor TARA or ERAS? In the previous week, Erasca had 4 more articles in the media than Protara Therapeutics. MarketBeat recorded 6 mentions for Erasca and 2 mentions for Protara Therapeutics. Erasca's average media sentiment score of 1.02 beat Protara Therapeutics' score of 0.58 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of TARA or ERAS? 38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 8.4% of Protara Therapeutics shares are held by company insiders. Comparatively, 14.4% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate TARA or ERAS? Protara Therapeutics currently has a consensus price target of $19.60, suggesting a potential upside of 528.21%. Erasca has a consensus price target of $4.29, suggesting a potential upside of 172.98%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Erasca 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryErasca beats Protara Therapeutics on 8 of the 14 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.38M$2.53B$5.76B$9.75BDividend YieldN/A1.68%3.96%4.02%P/E Ratio-1.9322.8042.8226.39Price / SalesN/A537.13431.37159.28Price / CashN/A177.0937.7559.42Price / Book0.835.9710.566.59Net Income-$44.60M$32.94M$3.27B$265.83M7 Day Performance0.32%-1.28%0.61%0.18%1 Month Performance-6.31%2.31%5.43%2.13%1 Year Performance54.46%10.85%50.37%21.07% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.5771 of 5 stars$3.12-0.6%$19.60+528.2%+57.8%$120.38MN/A-1.9330ERASErasca2.2262 of 5 stars$1.53-6.7%$4.29+180.1%-45.3%$465.22MN/A-3.40120News CoveragePositive NewsETONEton Pharmaceuticals2.4967 of 5 stars$16.37-3.9%$29.67+81.2%+275.7%$456.97M$39.01M-102.3120Positive NewsCGEMCullinan Therapeutics1.7582 of 5 stars$7.95+3.8%$28.60+259.7%-59.3%$452.51MN/A-2.4630TNXPTonix Pharmaceuticals2.8504 of 5 stars$40.07-22.0%$70.00+74.7%+2.6%$450.13M$10.09M-1.0250Positive NewsHigh Trading VolumeITOSiTeos Therapeutics2.9316 of 5 stars$10.11flat$15.50+53.3%-40.8%$446.92M$35M-2.1690Positive NewsGOSSGossamer Bio3.7814 of 5 stars$1.99+1.5%$8.50+327.1%+172.3%$445.67M$114.70M-3.21180News CoverageRGNXREGENXBIO4.3336 of 5 stars$8.71-1.2%$28.38+225.8%-23.4%$445.54M$83.33M-2.53370PRTAProthena3.4613 of 5 stars$8.53+3.4%$30.25+254.6%-61.2%$444.10M$135.16M-1.51130News CoverageAnalyst ForecastTECXTectonic Therapeutic2.4498 of 5 stars$24.71+5.1%$80.33+225.1%+34.9%$439.92MN/A-6.12120Positive NewsEOLSEvolus4.2344 of 5 stars$6.69-0.6%$21.25+217.6%-52.5%$435.33M$266.27M-6.83170Positive News Related Companies and Tools Related Companies ERAS Alternatives ETON Alternatives CGEM Alternatives TNXP Alternatives ITOS Alternatives GOSS Alternatives RGNX Alternatives PRTA Alternatives TECX Alternatives EOLS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access